Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	1/10/2007 11:42:50 AM
	of 946

>>7:00AM Cell Therapeutics files for Special Protocol Assessment With FDA for Xyotax lung cancer trial in women (CTIC) 1.72 : Co announces that it has filed for a Special Protocol Assessment with the FDA for the design of its phase III trial of Xyotax for women with advanced lung cancer. The trial, PGT306, will focus exclusively on women with normal estrogen levels, the subset where Xyotax demonstrated the greatest survival advantage in the Stellar trials. The trial is expected to enroll 300 poor performance status women who have advanced stage non-small cell lung cancer and have not received prior chemotherapy.<< Courtesy of briefing.com Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next